Transcription Elongation Factor A (SII)-like 2 (TCEAL2): A New Prognostic Marker for Cancer

The world faces the most deaths from cancer compared to any other illness. Patients with cancer suffer from intense physical pain while they also face significant financial hardships. We must urgently establish the pathogenic mechanisms and develop therapeutic solutions. The development of cancer follows a sequential mutagenic process involving multiple steps. The scientific community has identified numerous oncogenes and tumor suppressor genes that either drive or prevent tumor development and this knowledge has led to the creation of diagnostic and therapeutic drugs based on these genes.

Numerous genes have been identified yet scientists remain unclear about their biological functions and ineffective treatments exist. It is essential for researchers to discover more oncogenes and tumor suppressor genes in their ongoing studies. TCEAL2 protein operates as a transcription elongation factor-like protein and participates in diverse biological processes. Recent research interest in TCEAL2 has increased because this protein shows potential applications in both tumor development and cancer prognosis.

Related Product

TCEAL2 Structure

The nuclear phosphoprotein Transcription elongation factor A (SII)-like 2 (TCEAL2), also known as WEX1, my048 and MY0876G05 regulates transcription through promoter-dependent mechanisms and serves as an important nuclear target for signal transduction within cells. The TCEAL gene family encompasses 9 transcription elongation factor A (SII)-like members called TCEAL1 through TCEAL9 that share a common TFA domain. The TCEAL gene family members are all positioned on chromosome X and TCEAL2 specifically resides on chromosome Xq22.1. The human TCEAL2 mRNA consists of 1100 base pairs and translates into a protein that weighs 26 kDa with 227 amino acids. The primary structure of TCEAL2 consists of a leucine-rich domain. This protein does not contain any recognized catalytically active domain which implies that its function likely involves protein interactions. The presence of phosphorylation sites in this protein suggests that signaling pathways control its function.

Physiological functions of TCEAL2

TCEAL2 functions primarily to regulate gene expression while it influences cellular physiological processes by modulating transcription elongation. Its specific functions include:

Participating in Gene Transcription Regulation

TCEAL2 influences gene expression through its role as a transcriptional regulator by controlling RNA polymerase II activity. TCEAL2 may work with the chromatin remodeling complex to modify the chromatin state which results in the regulation of gene expression.

Cell Cycle Regulation

Research indicates that TCEAL2 influences cell proliferation through gene regulation of cell cycle components including Cyclins and CDKs.

The protein TCEAL2 likely performs regulatory functions during either the G1/S or G2/M cell cycle phases.

Cell Apoptosis and Survival

The protein influences cell survival through its involvement in both the p53-related pathway and the PI3K/AKT signaling pathway. TCEAL2 functions as a pro-apoptotic factor in certain cancers but supports cell survival mechanisms in other types of cancer.

Possible Cancer Relevance

TCEAL2 shows abnormal expression patterns in specific cancer types including breast cancer, lung cancer, and colorectal cancer. TCEAL2 has the potential to control tumor growth by influencing specific cellular signaling mechanisms including Wnt/β-catenin, MAPK, and PI3K/AKT pathways.

Subcellular Localization of TCEAL2

The TCEAL2 protein predominantly resides in the cell nucleus which supports its role as a transcriptional regulatory factor. TCEAL2 shows up in the cytoplasm within certain cell types which implies it performs unusual cellular roles.

Role of TCEAL2 in cancer

Gene Regulation and Tumorigenesis

TCEAL2 functions in gene transcription regulation and influences cancer cell growth and programmed cell death. Multiple cancer types including breast cancer, lung cancer, and liver cancer display abnormal levels of TCEAL2 expression according to scientific research.

Tumor Suppressor or Promoter

TCEAL2 functions as a tumor suppressor gene in certain cancers by blocking cell growth and triggering programmed cell death. Certain signaling pathways activate TCEAL2 in some cancers which promotes cancer cell survival and migration.

Signaling Pathway Association

The behavior of cancer cells can be influenced by TCEAL2 through its interaction with the Wnt/β-catenin pathway alongside the PI3K/AKT and MAPK signaling routes. The function of TCEAL2 could be linked to several processes including EMT (epithelial-mesenchymal transition) and DNA repair as well as cell cycle control.

TCEAL2 serves as a potential new marker for predicting clinical outcomes

Biomarker Characteristics

The expression of TCEAL2 shows possible connections to patient survival rates as well as risks for cancer recurrence and tumor advancement. The analysis of TCEAL2 expression patterns enables predictions about the degree of malignancy in specific cancer types.

Comparison with Traditional Markers

The accuracy of early diagnosis and prognostic assessment of cancer can be enhanced by using TCEAL2 together with traditional biomarkers like p53, Ki-67, and HER2.

Applicability to Multiple Cancer Types

The protein TCEAL2 seems to have a role in the development of multiple cancer types such as breast cancer, lung cancer, colorectal cancer, and hepatocellular carcinoma.

Combined Detection

TCEAL2 can serve to enhance early cancer diagnosis accuracy and prognostic evaluation when combined with standard biomarkers like Ki-67, p53, and HER2.

TCEAL2-related cancer signaling pathways

The Protein TCEAL2 Represents a Novel Effective Prognostic Marker for Cancer Diagnosis

TCEAL2 shows promise as a cancer prognostic marker but requires additional research to establish its precise function and clinical importance. TCEAL2 shows abnormal levels in several cancer types including breast, lung, colorectal, liver, and prostate cancer while influencing cell proliferation and cancer survival along with metastasis through Wnt, PI3K/AKT, and MAPK signaling pathways. This candidate holds potential as a cancer prognostic marker yet requires additional research to uncover its precise mechanisms and practical applications. The potential for future research to validate its reliable prognostic prediction ability could establish its significance as a key reference indicator for cancer diagnosis and treatment choices.

References

1. O'Keefe, E., et al. Trichohyalin: a structural protein of hair, tongue, nail, and epidermis. Journal of investigative dermatology. 1993, 101(1): S65-S71.
2. Rothnagel, J., et al. Trichohyalin, an intermediate filament-associated protein of the hair follicle. The Journal of cell biology. 1986, 102(4): 1419-1429.